JAMA · Nov 15, 2026

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial

By Zhao L, Chen Y, Cheng Z et al.

IMPORTANCE: Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. OBJECTIVE: To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted at 55 sites in China. From May to June 2024, adults without diabetes who had a body mass index of 28 or greater or 24 or greater with at least 1 weight-related comorbidity were enrolled, with final follow-up on June 20, 2025. INTERVENTIONS: Participants were randomized to receive once-weekly subcutaneous ribupatide (target doses of 2 mg, 4 mg, or 6 mg) or matching placebo for 48 weeks, with dose escalation for up to 20 weeks and concomitant lifestyle intervention. MAIN OUTCOMES AND MEASURES: The primary outcome was change in body weight from baseline to week 48, including percent change in body weight and the percentage of participants achieving at least 5% body weight reduction, analyzed under the treatment policy estimand. RESULTS: Among 567 randomized participants (309 [54.5%] female; mean [SD] age was 34.4 [8.4] years, body weight was 93.0 [17.3] kg, and body mass index was 33.3 [4.5]), 514 (90.7%) completed the 48-week treatment period. Least-squares mean percentage changes in body weight at week 48 were -10.7%, -16.4%, and -17.7% with ribupatide 2, 4, and 6 mg, respectively, vs -1.4% with placebo. At week 48, the placebo-adjusted differences in percentage change in body weight were -9.3 (95% CI, -11.4 to -7.3) percentage points with ribupatide 2 mg, -15.0 (95% CI, -17.1 to -12.9) percentage points with ribupatide 4 mg, and -16.3 (95% CI, -18.4 to -14.2) percentage points with ribupatide 6 mg (P < .001 for all). For at least 5% body weight reduction at week 48, the multiply imputed response rates were 68.1% (95% CI, 59.9% to 75.3%) for ribupatide 2 mg (97 of 142), 88.0% (95% CI, 81.3% to 92.6%) for ribupatide 4 mg (124 of 141), 85.7% (95% CI, 78.6% to 90.7%) with ribupatide 6 mg (121 of 141), and 16.0% (95% CI, 10.8% to 23.1%) with placebo (23 of 143). Placebo-adjusted differences for ribupatide 2, 4, and 6 mg were 52.0 (95% CI, 42.2 to 61.9), 72.0 (95% CI, 63.7 to 80.2), and 69.7 (95% CI, 61.1 to 78.3) percentage points, respectively (all P < .001). The most frequent treatment-emergent adverse events with ribupatide were gastrointestinal events, occurring in 47.9%, 58.2%, and 63.1% of participants receiving ribupatide 2 mg, 4 mg, and 6 mg, respectively, compared with 23.1% receiving placebo; most were mild to moderate in severity and few participants (0.7%) permanently discontinued study treatment because of adverse events. CONCLUSIONS AND RELEVANCE: Among adults in China with overweight or obesity without diabetes, once-weekly subcutaneous ribupatide resulted in significantly greater weight loss at 48 weeks. Gastrointestinal adverse events were the most frequent tolerability findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06396429.

doi.org/10.1001/jama.2026.24796PubMed 43035098Interventions

AgingResearch.News